The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.

FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment By Annika Kim Constantino,CNBC • Published January 21, 2025 • Updated on January 21, 2025 at 11:04 am BOOKMARKER ...

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug ...

In just over five minutes, Johnson & Johnson tackles the complicated nature of living with depression — both from the perspective of patients and caregivers — in a recently released short film.

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

A depression drug candidate that’s a key part of Johnson & Johnson’s neuroscience strategy has failed a Phase 3 clinical trial, the latest dose of disappointing news for an emerging class of ...

Beckley Psytech’s psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of a planned merger with mental health-focused company Atai Life ...

On Friday, Johnson & Johnson (NYSE:JNJ) decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa opioid receptor (KOR) antagonist, as an adjunctive treatment ...

While ALTO-203 missed its depression-related endpoints, improvements in EEG biomarkers, attention and wakefulness point to ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow. The ...